Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pluristem Therapeutc (PSTI)

Pluristem Therapeutc (PSTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Critical Limb Ischemia Drug Market 2019 Global Industry Trends, Statistics, Competition Strategies, Revenue Analysis, Key Players, Regional Analysis by Forecast to 2026

The global Critical Limb Ischemia Drug market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.This report focuses on Critical...

CLBS : 2.27 (-2.16%)
CYYNF : 1.1900 (-4.80%)
HEM.VN : 0.035 (+16.67%)
PSTI : 3.66 (-0.81%)
RNUGF : 1.5500 (-24.76%)
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs

-- PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantation

PSTI : 3.66 (-0.81%)
Critical Limb Ischemia Drug Market Analysed by Business Growth, Development Factors and Future Trends by 2026

In 2018, the Critical Limb Ischemia Drug Market revenue was around US$ XX Mn and the Market share was XX%, and it will be projected to reach US$ XX Mn and XX% in 2026, with a CAGR XX% during the forecast...

CLBS : 2.27 (-2.16%)
CYYNF : 1.1900 (-4.80%)
HEM.VN : 0.035 (+16.67%)
PSTI : 3.66 (-0.81%)
RNUGF : 1.5500 (-24.76%)
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs

Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced additional information relating to its live Key Opinion Leader...

PSTI : 3.66 (-0.81%)
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced the...

PSTI : 3.66 (-0.81%)
BVXV : 5.55 (+1.15%)
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will host a live Key...

PSTI : 3.66 (-0.81%)
Critical Limb Ischemia Drug Market Is Growing At an Exponential Rate in 2019 and Coming Years

The global Critical Limb Ischemia Drug market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2019 to 2026.

CLBS : 2.27 (-2.16%)
CYYNF : 1.1900 (-4.80%)
HEM.VN : 0.035 (+16.67%)
PSTI : 3.66 (-0.81%)
RNUGF : 1.5500 (-24.76%)
Global Critical Limb Ischemia Drug Market Insights, Forecast to 2019 Analysis by Application, Size, Production, Market Share, Consumption, Trends and Forecast 2025

The market size of Critical Limb Ischemia Drug is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will...

CLBS : 2.27 (-2.16%)
CYYNF : 1.1900 (-4.80%)
HEM.VN : 0.035 (+16.67%)
PSTI : 3.66 (-0.81%)
RNUGF : 1.5500 (-24.76%)
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome

-- Data is jointly presented at the 2019 Radiation Injury Treatment Network (RITN) Workshop

PSTI : 3.66 (-0.81%)
Pluristem Therapeutics' CEO Issues Shareholders Update

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its...

PSTI : 3.66 (-0.81%)
Pluristem Announces One-for-Ten Reverse Split of its Common Shares

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that, its Board of Directors has approved...

PSTI : 3.66 (-0.81%)
Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN

-- Data will be jointly presented at the upcoming 2019 Radiation Injury Treatment Network (RITN) Workshop on July 31st

PSTI : 3.66 (-0.81%)
Pluristem Therapeutics' CEO Issues Shareholder Letter

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its...

PSTI : 3.66 (-0.81%)
Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the completion of the transition period...

PSTI : 3.66 (-0.81%)
Lead Physicians in Pluristem's Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, announced the publication of a peer-reviewed article...

PSTI : 3.66 (-0.81%)
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has filed a U.S. provisional...

PSTI : 3.66 (-0.81%)
Recent Analysis Shows OneMain, E*TRADE Financial, Keurig Dr Pepper, and Pluristem Therapeutics Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of OneMain Holdings, Inc. (NYSE:OMF),...

OMF : 36.23 (-0.52%)
ETFC : 39.01 (-2.12%)
KDP : 27.61 (+0.29%)
PSTI : 3.66 (-0.81%)
Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has achieved a significant...

PSTI : 3.66 (-0.81%)
Pluristem Therapeutics Issues Shareholder Update

-- Recent financing provides funding through multiple potentially value-creating milestones

PSTI : 3.66 (-0.81%)
Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million

Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) ("Pluristem" or "Company"), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today...

PSTI : 3.66 (-0.81%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.04 , AIZ -0.01 , SBAC -6.07 , SO +0.39 , WELL -0.37
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar